Original Title: Plasma rico en plaquetas en fracturas y pseudoartrosis de los huesos largos

Authors' recommendations: CONCLUSIONS Moderate quality evidence shows that platelet-rich plasma used to treat long bone fractures is not associated to better clinical or radiological outcomes than conventional treatment. Evidence of moderate quality coming from a small study shows that adding platelet-rich plasma to autologous bone graft to treat long-bone pseudoarthrosis was related to better clinical outcomes and higher healing rate than the use of autologous bone graft only. Moderate quality evidence shows that platelet-rich plasma was inferior to the use of another osteogenesis stimulating factor, the human recombinant bone morphogenetic protein 7. The collected evidence does not describe severe complications associated to the procedure, however its long-term safety is unknown. No cost-efficiency studies or related to the financial impact of the procedure have been found. State-owned sponsors from Argentina and the rest of the countries assessed do not mention platelet-rich plasma as a treatment for long bone fracture or pseudoarthrosis; three United States private sponsors do not cover it. One clinical practice guideline on the use of platelet-rich plasma does not support its use to treat pseudoarthrosis, while other guidelines consulted do not mention it.

Project Status: Completed

Year Published: 2017

URL for published report: https://www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)